Literature DB >> 20309840

Orthogonal predictions: follow-up questions for suggestive data.

Alexander M Walker1.   

Abstract

When a biological hypothesis of causal effect can be inferred, the hypothesis can sometimes be tested in the selfsame database that gave rise to the study data from which the hypothesis grew. Valid testing happens when the inferred biological hypothesis has scientific implications that predict new relations between observations already recorded. Testing for the existence of the new relations is a valid assessment of the biological hypothesis, so long as the newly predicted relations are not a logical correlate of the observations that stimulated the hypothesis in the first place. These predictions that lead to valid tests might be called 'orthogonal' predictions in the data, and stand in marked contrast to 'scrawny' hypotheses with no biological content, which predict simply that the same data relations will be seen in a new database. The Universal Data Warehouse will shortly render moot searches for new databases in which to test. (c) 2010 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2010        PMID: 20309840     DOI: 10.1002/pds.1929

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  8 in total

1.  A decade of data mining and still counting.

Authors:  Manfred Hauben; G Niklas Norén
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

2.  Identifying signals of interest when screening for drug-outcome associations in health care data.

Authors:  Anton Pottegård; Jesper Hallas; Shirley V Wang; Joshua J Gagne
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

3.  Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network.

Authors:  Carmen Ferrajolo; Preciosa M Coloma; Katia M C Verhamme; Martijn J Schuemie; Sandra de Bie; Rosa Gini; Ron Herings; Giampiero Mazzaglia; Gino Picelli; Carlo Giaquinto; Lorenza Scotti; Paul Avillach; Lars Pedersen; Francesco Rossi; Annalisa Capuano; Johan van der Lei; Gianluca Trifiró; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2014-02       Impact factor: 5.606

4.  A basic study design for expedited safety signal evaluation based on electronic healthcare data.

Authors:  Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-08       Impact factor: 2.890

5.  Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event.

Authors:  Shirley V Wang; Kristina Stefanini; Edwin Lewis; Sophia R Newcomer; Bruce Fireman; Matthew F Daley; Jason M Glanz; Jonathan Duffy; Eric Weintraub; Martin Kulldorff
Journal:  Drug Saf       Date:  2020-10       Impact factor: 5.606

6.  Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.

Authors:  Marc L Berger; Harold Sox; Richard J Willke; Diana L Brixner; Hans-Georg Eichler; Wim Goettsch; David Madigan; Amr Makady; Sebastian Schneeweiss; Rosanna Tarricone; Shirley V Wang; John Watkins; C Daniel Mullins
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-09       Impact factor: 2.890

7.  Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance.

Authors:  Andrew Bate; Ken Hornbuckle; Juhaeri Juhaeri; Stephen P Motsko; Robert F Reynolds
Journal:  Ther Adv Drug Saf       Date:  2019-08-05

8.  Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data.

Authors:  Nicolas H Thurin; Pauline Bosco-Levy; Patrick Blin; Magali Rouyer; Jérémy Jové; Stéphanie Lamarque; Séverine Lignot; Régis Lassalle; Abdelilah Abouelfath; Emmanuelle Bignon; Pauline Diez; Marine Gross-Goupil; Michel Soulié; Mathieu Roumiguié; Sylvestre Le Moulec; Marc Debouverie; Bruno Brochet; Francis Guillemin; Céline Louapre; Elisabeth Maillart; Olivier Heinzlef; Nicholas Moore; Cécile Droz-Perroteau
Journal:  BMC Med Res Methodol       Date:  2021-05-01       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.